NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing ...
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today ...
Under30CEO on MSN
How Epinal’s Narcolyzer addresses a growing emergent need for non-invasive, rapid, handheld narcotics testing
Public institutions across the world are reassessing how they identify and respond to narcotic impairment. Courts, ...
NeOnc, a biotech company helmed by Dr. Thomas Chen, brings the first non-invasive intranasal drug delivery for brain cancer into the spotlight. With this revolutionary treatment, NeOnc is poised to ...
Intelligent Bio Solutions Inc. (INBS) has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a rapid and non-invasive drug testing method ...
(RTTNews) - Intelligent Bio Solutions Inc. (INBS) announced Wednesday the rapid expansion of its Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark through its ...
The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback